Philips completes acquisition of The Spectranetics Corporation

Acquisition expands and strengthens Philips’ image-guided therapy business group

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of The Spectranetics Corporation (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation(NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions.

Spectranetics' device portfolio includes a range of catheters to treat coronary and peripheral artery disease, and the removal of implanted pacemaker and implantable cardioverter defibrillator leads. The Stellarex drug-coated balloon is a key growth driver in this portfolio. It is a next generation drug-coated balloon that provides proven peripheral artery disease treatment and is backed by robust clinical evidence. The Stellarex drug-coated balloon is CE-marked and recently obtained U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA).

Philips Image Guided Therapy

As the leader in image guided therapy, we are committed to working with healthcare providers to help improve treatment for every patient.

Our vision is to provide integrated solutions that advance minimally invasive procedures by helping healthcare providers to decide, guide, treat and confirm the right therapy for the right patient at the point of care. Working together to realize this vision, we can save and improve lives and reduce the total cost of care by making therapy more efficient, more appropriate and more personal.

We will help to ensure these solutions endure over time and continue to deliver value in the lab by providing the right in-lab support. These are the unique, specific capabilities that Philips Image Guided Therapy brings to our customers that will enable us to realize this vision together.

Lead Management

Introducing the

iFR Co-registration

Cardiology

Philips is a global image guided therapy leader that provides solutions to help optimize and streamline PCI. We are committed to working with health care providers to improve treatment for every patient using our leading coronary IVUS, pressure and flow based technologies. Our integrated product offerings help clinicians decide, guide and confirm the right therapy for each patient at the point of care.

Peripheral

Discover the suite of products designed by Philips to help diagnose and treat peripheral disease. Review IVUS-guided stenting clinical evidence, access procedural tools, case reviews, and more. View our full line of peripheral vascular intervention strategies, tools and resources that can help you decide, guide, treat, and confirm.

Advanced Imaging Systems

Designed to power the future of precision guided therapy, Philips provides clarity in your approach and confidence in your results with a full suite of imaging and physiology analysis tools. With the choice of FFR, iFR and IVUS modalities on a single integrated platform, we deliver convenience in your workflow with true integration. IVUS and iFR co-registration are now available on the SyncVision advanced imaging system.

Lead Management

Managing cardiac implantable electronic device (CIED) leads has never been more important. Patients with CIEDs are on a lifelong journey, and Spectranetics is there to make sure it’s a healthy one. Making the right decision at the right time, for every patient, is critical. Lives depend on it. Explore the link below to learn more about Lead Management and the products that ensure lead extraction is done safely, responsibly and predictably.

Integrated solutions: labs of the future

The future of guidance and therapies depends on great product development, partnerships to help support the clinical community and improving outcomes for patients and practices. Leaders in interventional cardiovascular solutions discuss their vision.

Bert van Meurs, CEO Image Guided Therapy

“I envision a time when all surgical procedures will be done through minimally invasive treatment, supported by intelligent imaging systems and devices.”

Dr. Carlos Ruiz shares his thoughts on the possibilities through integration

Play

Dr. Jorge Belardi shares his thoughts on the benefits of integration

By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.